AUS
NZ
UK
CA
USA
IND
Highlights
- Recce secures patent approval in China for key anti-infective drug candidates.
- Patent covers multiple bacterial and viral infections with varied administration methods.
- Expansion enhances Recce’s global intellectual property footprint in major pharmaceutical markets.
Recce Pharmaceuticals Ltd (ASX:RCE) continues to make significant strides in the pharmaceutical industry by securing a crucial patent approval in China for its innovative synthetic anti-infective drug candidates, RECCE® 327 (R327) and RECCE® 529 (R529). This newly accepted patent extends Recce’s intellectual property protection through to 2041 and marks its fifth granted patent under Patent Family 4, complementing existing approvals in Australia, Canada, Israel, and Japan.
The Chinese pharmaceutical market ranks as the world’s second-largest and offers tremendous growth potential. Antibiotics alone in this market are projected to reach a valuation of approximately US$4.09 billion by 2030, growing at a compound annual growth rate of 5.7%. Given the increasing global challenge posed by antibiotic resistance, Recce’s expanded patent coverage positions the company well to contribute to this evolving healthcare landscape.
The granted patent includes protections for both the manufacturing process and medical applications of R327 and R529. These drug candidates are designed to combat a wide variety of bacterial and viral infections such as acute bacterial skin and skin structure infections (ABSSSI), diabetic foot infections, burn wounds, pneumonia including ventilator- and hospital-acquired cases, urinary tract infections, gonorrhoea, influenza, and even SARS-CoV-2. Moreover, the patent covers diverse routes of administration — oral, inhalation, transdermal, and injections — along with several formulation types including aerosols, gels, topical foams, and impregnated dressings.
This strategic expansion of patent rights reflects Recce’s ongoing commitment to securing robust intellectual property in major pharmaceutical markets worldwide. Additional Patent Cooperation Treaty (PCT) applications are progressing in multiple jurisdictions, further strengthening the company's global position.
Recce’s progress in expanding its patent portfolio also highlights its growing prominence among ASX200 companies, with the pharmaceutical sector gaining attention from investors interested in sustainable health solutions. For those exploring ASX dividend stocks, pharmaceutical innovators like Recce present compelling cases due to their strong intellectual property and market potential.
As part of its development pipeline, Recce is advancing R327 through clinical trials targeting serious bacterial infections and sepsis. The drug has earned notable designations from the U.S. Food and Drug Administration, enhancing its profile in the global health sector. Recce also continues development of R435, an oral antibiotic, and R529, an antiviral candidate.
With recognition from international health bodies such as the World Health Organization and The Pew Charitable Trusts, Recce Pharmaceuticals (RCE) is well positioned to address antimicrobial resistance challenges while contributing to the broader pharmaceutical growth story in the ASX200 index.
